Modest Cuts in Antibiotic Use Could Avert 38,000 AMR Deaths Yearly

A global analysis linking antibiotic consumption to antimicrobial resistance suggests that even achievable reductions in drug use would deliver smaller near-term gains against resistant infections than many stewardship advocates might hope. Drawing on surveillance data covering more than 30 million bacterial isolates from 114 countries between 2000 and 2018, researchers estimated how population-level antibiotic exposure relates to the prevalence of resistance across 16 bacterial pathogens and seven antibiotic drug classes. The team, led by Benjamin J. Singer and Joseph A. Lewnard, combined country- and year-specific estimates of antibiotic consumption with resistance prevalence data, using weighted regression models that adjusted for country-level health and development indicators.

Rather than assuming a simple linear link, the analysis estimated elasticity relationships, capturing how proportional changes in drug exposure correspond to proportional changes in resistance prevalence for each pathogen and drug class combination. The statistical signal linking antibiotic use to resistance was strongest for five major pathogens: Acinetobacter species, Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. The strength of these associations with consumption patterns is a central finding for policymakers weighing restrictive prescribing rules against clinical access, particularly where gaps in antibiotic access persist.

To translate these statistical associations into a concrete estimate, the researchers modeled a counterfactual scenario in which antibiotic use across all seven drug classes fell by 10 percent relative to current levels. In that scenario, they calculated that roughly 38,000 fewer people would die each year from infections attributable to antimicrobial resistance, with a 95 percent confidence interval running from 36,000 to 41,000 deaths averted annually. That figure is substantial in absolute terms, yet the study places it in sobering context.

The avertable deaths represent only about 0.50 percent of estimated global mortality from bacterial disease. The gap is even starker in sub-Saharan Africa, where the risk of death from bacterial infection is greatest; there, the modeled reduction in resistance-attributable deaths amounts to just 0.34 percent of bacterial disease mortality. This asymmetry underscores a persistent tension in global health policy.

Antibiotic stewardship is intended to discourage use in situations where resistance-related harms outweigh clinical benefit, but the evidence needed to assess those tradeoffs has been lacking, most notably in low-resource settings where gaps in antibiotic access persist. The authors argue that the balance between restrictive and permissive antibiotic use paradigms must be evaluated in epidemiologically distinct settings rather than applied uniformly. The findings arrive as countries navigate commitments under the 2024 UN General Assembly resolution, which set targets for reducing the burden of antimicrobial resistance by 2030.

The researchers caution that their estimates rest on ecological relationships, inferring modifiable burden from population-level correlations rather than individual-level causal data. Surveillance coverage also underrepresents low-resource settings, both for antibiotic consumption and for resistance prevalence, which may bias elasticity estimates in ways that are difficult to quantify. Even so, the study's central message is measured: near-term reductions in resistance-attributable deaths achievable through lower antibiotic use are likely modest relative to the persisting global toll of bacterial disease mortality, and stewardship strategies should be calibrated accordingly.

Subject of Research: The relationship between population-level antibiotic consumption and antimicrobial resistance burden across 114 countries

Article Title: Burden of bacterial antimicrobial resistance associated with modifiable human antibiotic consumption: An observational study

Article References: Singer, B. J., Gleason, A., Impalli, I., Nagorsen, M. D., Chae, C., Granskog, L. C., Lee, P. C., Laxminarayan, R., & Lewnard, J. A. (2026). Burden of bacterial antimicrobial resistance associated with modifiable human antibiotic consumption: An observational study. PLOS Medicine, 23(10), e1005140. https://doi.org/10.1371/journal.pmed.1005140

Image Credits: AI Generated

DOI: 10.1371/journal.pmed.1005140

Keywords: antimicrobial resistance, antibiotic consumption, antibiotic stewardship, global health, bacterial pathogens, observational study, surveillance data, AMR mortality, sub-Saharan Africa, UN General Assembly resolution, Burden, bacterial